Gelesis

Gelesis is a clinical-stage biotechnology company developing first-in-class therapies to safely treat obesity, overweight, and diabetes patients. Gelesis aims to potentially alter the course of chronic diseases by mechanically influencing the GI pathway. Currently, the company's developed Gelesis100 has received FDA approval for weight management assistance. Gelesis is planning to develop a second drug candidate, Gelesis200, an optimized hydrogel designed for weight loss.